Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Statistical analysis for Therapeutic TNF-inhibitor gene therapy study:

From: Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis

  Normal ID ID+AdTNFRI
CD4 0.34 ± 0.091 1.20 ± 0.45 0.80 ± 0.34
Anova p < 0.0001    
   Normal   p < 0.0001 p = 0.008
   ID    p = 0.0003
CD8 0.49 ± 0.08 0.47 ± 0.14 1.63 ± 0.94
Anova p < 0.0001    
   Normal   p = 1.00 p = 0.0002
   ID    p < 0.0001
RTLA 1.65 ± 0.84 13.2 ± 4.29 7.17 ± 2.81
Anova p < 0.0001    
   Normal   p < 0.0001 p = 0.0001
   ID    p < 0.0001
CD18 0.17 ± 0.08 9.68 ± 2.55 5.53 ± 2.32
Anova p < 0.0001    
   Normal   p < 0.0001 p < 0.0001
   ID    p < 0.0001
  1. 1 Mean ± SD
  2. 2 Pairwise comparison p-value with a Bonferroni correction.
  3. ID = induced dacryoadenitis; ANOVA = analysis of variance.
  4. Compared to ID group, AdTNFRI treated lacrimal glands have a significant decrease of CD4+ (p = 0.0003), RTLA+ (p < 0.0001) and CD18+ cells (p < 0.0001), and a significant increase of CD8+ cells in these treated glands (p < 0.0001).